First COVID-19 vaccine human trial finds it is safe, induces immune response
24 May, 2020
The first COVID-19 vaccine to reach phase I clinical trial is safe, well-tolerated, and capable of generating an immune response against the novel coronavirus in humans, says a new research published in The Lancet journal.
According to the study of 108 adults, the vaccine produced neutralising antibodies, and a response mediated by the immune system”s T-cells against the novel coronavirus,